...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Characteristics of intestinal absorption and disposition of glycyrrhizin in mice.
【24h】

Characteristics of intestinal absorption and disposition of glycyrrhizin in mice.

机译:甘草甜素在小鼠中的肠道吸收和吸收特性。

获取原文
获取原文并翻译 | 示例

摘要

As basic studies to apply an intestinal pressure-controlled colon delivery capsule (PCDC) for glycyrrhizin (GZ), the characteristics of intestinal absorption and disposition of GZ were investigated in mice. In the in vivo study, after intravenous (iv) administration of GZ, 10 mg/kg dose, plasma GZ disappeared from the systemic circulation with t(1/2(alpha)) of 0.0063 h, thereafter, it slowly declined with t(1/2(beta)) of 15.23 h. The area under the plasma drug concentration versus time curve (AUC) values of iv (10 mg/kg), intracolonic (50 mg/kg) and intraduodenum (50 mg/kg) administrations were 115.1, 16.7 and 2.7 microgh/mL, respectively. The AUC values of plasma glycyrrhetic acid (GA), a degradation product after intracolonic and intraduodenum administrations were 2.8 and 8.4 microgh/mL, respectively. In the in situ closed loop study, the concentrations of GZ in plasma and liver after intracolonic administration were significantly increased (p<0.05) in comparison with those after intrajejunum or intraileum administration, while the concentration of GA in plasma and liver after intracolonic administration had trends to increase. These observations clearly suggest that the intracolonic administration is a useful way to improve the oral bioavailability of GZ and to enhance its pharmacological efficacy. These pharmacokinetic results of GZ suggest that GZ is a subject drug to be applied for the PCDC system we previously developed. The PCDCs formulation of GZ will enable us to carry GZ to the colon and enhance the oral bioavailability of GZ. Copyright 2000 John Wiley & Sons, Ltd.
机译:作为将肠道压力控制结肠递送胶囊(PCDC)用于甘草甜素(GZ)的基础研究,研究了小鼠的肠道吸收和GZ处置特性。在体内研究中,静脉内(iv)施用10 mg / kg剂量的GZ后,血浆GZ从体循环中消失,t(1 /2α)为0.0063 h,此后随着t(1/2)缓慢下降。 15.23小时的1 /2β)。静脉内(10 mg / kg),结肠内(50 mg / kg)和十二指肠内(50 mg / kg)给药的血浆药物浓度-时间曲线(AUC)值分别为115.1、16.7和2.7 microgh / mL。 。结肠内和十二指肠内给药后的降解产物血浆甘草次酸(GA)的AUC值分别为2.8和8.4 microgh / mL。在原位闭环研究中,与空肠内或回肠内给药相比,结肠内给药后血浆和肝脏中GZ的浓度显着增加(p <0.05),而结肠内给药后血浆和肝脏中GA的浓度有升高趋势增加。这些观察清楚地表明,结肠内给药是改善GZ的口服生物利用度并增强其药理效力的有用方法。 GZ的这些药代动力学结果表明,GZ是要用于我们先前开发的PCDC系统的主题药物。 GZ的PCDCs配方将使我们能够将GZ携带到结肠并增强GZ的口服生物利用度。版权所有2000 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号